United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 1,260 shares of the stock in a transaction on Thursday, April 20th. The shares were sold at an average price of $121.14, for a total transaction of $152,636.40. Following the transaction, the chief executive officer now directly owns 1,400 shares in the company, valued at approximately $169,596. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Shares of United Therapeutics Co. (NASDAQ:UTHR) traded down 0.19% during midday trading on Friday, reaching $120.98. 828,522 shares of the company’s stock were exchanged. The stock has a market cap of $5.44 billion, a PE ratio of 7.93 and a beta of 1.42. The stock’s 50 day moving average is $135.24 and its 200-day moving average is $137.86. United Therapeutics Co. has a 12-month low of $97.52 and a 12-month high of $169.89.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, February 22nd. The biotechnology company reported $4.12 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.61 by $0.51. United Therapeutics had a net margin of 44.40% and a return on equity of 41.78%. The company had revenue of $409 million for the quarter, compared to analysts’ expectations of $415.51 million. During the same period in the prior year, the business earned $3.80 EPS. The firm’s quarterly revenue was up 1.0% on a year-over-year basis. On average, equities analysts expect that United Therapeutics Co. will post $14.23 EPS for the current year.

Insider Buying and Selling by Quarter for United Therapeutics (NASDAQ:UTHR)

COPYRIGHT VIOLATION WARNING: This report was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/04/21/united-therapeutics-co-uthr-ceo-sells-152636-40-in-stock.html.

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Ladenburg Thalmann Financial Services Inc. boosted its position in shares of United Therapeutics by 11.3% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 717 shares of the biotechnology company’s stock valued at $104,000 after buying an additional 73 shares during the last quarter. Focused Wealth Management Inc acquired a new position in shares of United Therapeutics during the fourth quarter valued at about $115,000. Cigna Investments Inc. New acquired a new position in shares of United Therapeutics during the fourth quarter valued at about $236,000. First Republic Investment Management Inc. acquired a new position in shares of United Therapeutics during the fourth quarter valued at about $236,000. Finally, Zweig DiMenna Associates LLC acquired a new position in shares of United Therapeutics during the third quarter valued at about $224,000.

Several research firms recently commented on UTHR. Oppenheimer Holdings Inc. reaffirmed a “buy” rating on shares of United Therapeutics in a report on Monday, April 3rd. Wedbush reaffirmed an “outperform” rating and set a $229.00 target price on shares of United Therapeutics in a report on Friday, January 27th. Jefferies Group LLC lowered shares of United Therapeutics from a “hold” rating to an “underperform” rating and reduced their target price for the company from $149.47 to $116.00 in a report on Monday, March 6th. Zacks Investment Research lowered shares of United Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, December 28th. Finally, HC Wainwright reaffirmed a “hold” rating and set a $95.00 target price on shares of United Therapeutics in a report on Monday. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and two have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $137.42.

United Therapeutics Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

5 Day Chart for NASDAQ:UTHR

Receive News & Stock Ratings for United Therapeutics Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Co. and related stocks with our FREE daily email newsletter.